MetaCap

Gelteq (GELS) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GELS-51.78%XBIO-36.65%
+3%-26%-55%
Oct 7, 20261 yearNov 20, 2026
GELS-48.18%XBIO-34.27%
+2%-24%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GELS versus XBIO key metrics
MetricGELSXBIO
Share price$0.2701$1.40
Market cap$3.11M$3.28M
1-day change-3.74%-9.09%
EPS (TTM)$-0.44$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.98M
Revenue growth (YoY)—+19.04%
Net income (latest FY)$-6.65M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$2.01$4.94
52-week low$0.255$1.25
Distance from 52-week high-86.56%-71.65%
Average volume2.85M73.30K
Shares outstanding11.51M2.34M
Employees72
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Gelteq

GELS stock →

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

GELS vs XBIO FAQ

Which is bigger, Gelteq or Xenetic Biosciences?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.11M for Gelteq (GELS).

Are Gelteq and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons